Background: There is a need for biomarkers in accessible matrices, such as blood, for the diagnosis of neurodegenerative diseases. The aim of this study was to measure the serum levels of brain-type fatty acid-binding protein (FABP) and heart-type FABP in patients with dementia-involving diseases.
Methods: Brain- and heart-type FABP were measured in serum samples from patients with either Alzheimer's disease (AD) (n = 31), Parkinson's disease (PD, n = 43), or other cognitive disorders (OCD, n = 42) and in 52 healthy controls. The localization of brain- and heart-type FABP was determined in brain sections by immunohistochemistry.
Results: Brain-type FABP levels were elevated in serum of 29%, 35%, and 24% of the patients with AD, PD, and OCD, respectively, and in 2% of the healthy donors. Heart-type FABP serum levels were not different amongst the patient groups. Brain-type and heart-type FABP expression was observed in reactive astrocytes in brain sections of patients with AD.
Conclusions: In contrast to heart-type FABP, serum levels of brain-type FABP are elevated in a significant proportion of patients with various neurodegenerative diseases and can therefore have importance for defining subgroups of these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1468-1331.2010.03273.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An electrochemiluminescence biosensor based on silver-cysteine nanorod as an emitter and AgNP-decorated FeMoO as a signal amplifier for sensitive detection of heart-type fatty acid binding protein.
Mikrochim Acta
December 2024
State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, 541004, China.
An electrochemiluminescence (ECL) immunosensor was developed for the highly sensitive and specific detection of heart-type fatty acid binding protein (H-FABP) and the rapid diagnosis of acute myocardial infarction (AMI). H-FABP is a biomarker that is highly specific to cardiac tissue and is associated with a range of cardiac diseases. Following myocardial injury, the rate of increase in H-FABP levels is greater than that observed for myoglobin and troponin.
View Article and Find Full Text PDFNovel Biomarkers as Potential Predictors of Decompensated Advanced Chronic Heart Failure-Single Center Study.
J Clin Med
November 2024
Department for Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, 48149 Münster, Germany.
Heart failure (HF) remains a major therapeutic and diagnostic challenge nowadays. Albeit, acute decompensated HF is associated with several clinical signs such as dyspnea or edema, it remains a challenge to use easy accessible and suitable tools, such as biomarkers, to distinguish between patients at risk for an acute decompensation of their heart failure and compensated, stable HF patients. Existing biomarkers, such as natriuretic peptides or troponin, are not specific and can be elevated due to several other disease conditions, such as myocardial infarction, atrial fibrillation, or valve diseases.
View Article and Find Full Text PDFEvaluation of diagnostic performances of Pro-neurotensin and Heart-type fatty acid binding protein as reliable biomarkers for cardiovascular diseases.
J Immunoassay Immunochem
January 2025
Department of Biochemistry, Faculty of Science, Helwan University, Cairo, Egypt.
Aim: In 2019, cardiovascular diseases accounted for 32% of global deaths. So, early detection of cardiac disorders is crucial. The study aimed to examine the suitability of Pro-neurotensin and Heart-type fatty acid binding protein as dependable biomarkers for cardiac patients with Heart failure as a primary diagnosis.
View Article and Find Full Text PDFManagement of Acute Pulmonary Embolism: A Review.
J Assoc Physicians India
November 2024
Consultant and Head, Department of Cardiology, Safdarjung Hospital, Delhi, India.
Article Synopsis
- Pulmonary embolism (PE) is a significant health concern in India, often missed or poorly managed, leading to increased risk of cardiovascular issues in hospitalized patients.
- Current research and studies have improved understanding of PE diagnosis, assessment, and treatment strategies, emphasizing the need for risk stratification of patients based on mortality risk.
- Recommended treatments include the use of anticoagulants and thrombolytics, with oral anticoagulants like warfarin and newer options (NOACs) being preferred for their ease of use and effectiveness at the time of diagnosis.
Correlation of serum H-FABP, sTREM-1, and HMGB1 levels with severity and prognosis of sepsis.
Am J Transl Res
October 2024
Emergency Department, West China Hospital of Sichuan University Chengdu 610000, Sichuan, China.
Objective: To investigate the correlation between serum levels of Heart-type fatty acid binding protein (H-FABP), Soluble Triggering Receptor Expressed on Myeloid Cells 1 (sTREM-1), and High mobility group box 1 protein (HMGB1) with disease severity, and their prognostic value in sepsis.
Methods: A retrospective analysis was conducted using the clinical data from 86 sepsis patients admitted to West China Hospital of Sichuan University between June 2021 and December 2023, and these cases constituted the observation group. In addition, clinical data from 80 healthy individuals who underwent medical examinations at our hospital during the same period served as the control group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!